Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

Rhea-AI Summary

Agenus (NASDAQ: AGEN), an immuno-oncology company, will release its first-quarter 2023 financial results on May 9, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss results and corporate updates. The call can be accessed via dial-in or a live webcast from the Company’s events page. Agenus is focused on developing therapies that leverage the immune system for cancer treatment, utilizing various therapeutics, including antibody agents and cell therapies. The Company aims to expand the reach of cancer immunotherapy by pursuing a range of combination therapies. For more information, visit their website.

Positive

• Focus on innovative immuno-oncology therapies may drive future growth.
• Plans to discuss financial results could instill confidence among investors.

Negative

• No specific financial metrics or growth figures provided in the PR, leading to uncertainty.

Conference Call on Tuesday, May 9, 2023 at 8:30 a.m. ET

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced the Company will release its first quarter 2023 financial results before the market opens on Tuesday, May 9, 2023. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call
Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Conference ID: 9144113

Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/v54y2wy9.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005395/en/

Agenus Inc.

Zack Armen

Head of Investor Relations

917-362-1370

zack.armen@agenusbio.com

Source: Agenus

FAQ

When will Agenus release its first-quarter 2023 financial results?

Agenus will release its first-quarter 2023 financial results on May 9, 2023.

What time is the conference call for Agenus' financial results?

The conference call will be held at 8:30 a.m. ET on May 9, 2023.

How can I listen to the Agenus conference call?

You can listen to the conference call by dialing in or accessing the live webcast on Agenus' events page.

What is the focus of Agenus as a company?

Agenus specializes in developing immuno-oncology therapies that engage the immune system to fight cancer.